Invitrogen™ Pimivalimab Recombinant Monoclonal Antibody

Pimivalimab, also known as JTX-4014, is a promising anti-PD-1 inhibitor primarily employed in oncology treatments. This biosimilar, located in the immunoglobulin superfamily (IgSF), is strategically designed to target the PD-1 receptor found on T-cells. The gene PDCD1, also known as PD-1 or CD279, encodes Programmed Cell Death Protein 1, a crucial immune checkpoint receptor expressed on T cells and other immune cells. Located on chromosome 2q37.3, PDCD1 consists of five exons. PD-1 is a type I transmembrane protein within the CD28/CTLA-4 superfamily and functions primarily to inhibit immune responses, thus maintaining peripheral tolerance and preventing autoimmune reactions. Upon binding to its ligands, PD-L1 and PD-L2, expressed on tumor cells and other tissues, PD-1 mediates the suppression of T-cell activity, inducing apoptosis in antigen-specific T cells while sparing regulatory T cells, contributing significantly to immune evasion by tumors.